A Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Intravenous Or Subcutaneous Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06741086 In Healthy Subjects And An Open-label Evaluation In Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2016
At a glance
- Drugs Marstacimab (Primary) ; Marstacimab (Primary)
- Indications Haemophilia
- Focus Adverse reactions
- Sponsors Pfizer
- 10 Aug 2016 Status changed from recruiting to completed.
- 26 May 2016 Planned End Date changed from 1 Aug 2016 to 1 Jul 2016.
- 26 May 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Jul 2016.